SELEX Platform

Tek Biotech is committed to providing customers with high-affinity and high-specificity nucleic acid aptamer screening technology services to provide strong support for customers' subsequent aptamer function validation (including, but not limited to, affinity validation, competitive ELISA validation, in vitro target cell function validation (e.g., in vitro recognition and inhibition of nucleic acid aptamers, in vitro flow blocking function, etc.), in vivo function validation (e.g., in vivo targeted inhibition of aptamers, signaling pathway blocking function, etc.) and downstream research and development work, such as targeting specific molecules for drug development.  Tek Biotech has many years of experience in nucleic acid aptamer screening (SELEX technology), and after years of development, Tek Biotech has established a comprehensive nucleic acid aptamer screening system, which is capable of providing high-quality nucleic acid aptamer (including RNA aptamer and DNA aptamer) screening services for customers in the target areas of proteins, peptides, amino acids, and small molecule compounds.

Nucleic acid aptamer screening refers to the systematic evolution of ligands by exponential enrichment (SELEX) based on the principle of binding the screening target on the surface of the screening solid-phase particles, and through incubation, cleaning and amplification with the nucleic acid aptamer library, the target oligonucleotide fragments (DNA fragments or RNA fragments) are obtained from the nucleic acid aptamer library. The target oligonucleotide fragment (DNA fragment or RNA fragment) is obtained from the nucleic acid aptamer library through incubation, cleaning and amplification with the nucleic acid aptamer library. Tek Biotech's aptamer libraries have a capacity of 10^10-10^11, which is sufficient for screening small molecule aptamers against various targets and meeting customers' downstream experimental needs. Based on the SELEX technology platform, Tek Biotech can screen nucleic acid aptamers with affinities in the nM-pM range. Tek Biotech can also provide a variety of downstream validation experiments, including but not limited to affinity validation of nucleic acid aptamers (including BLI affinity validation and SPR affinity validation), competitive ELISA validation, flow blocking validation, etc. Customers only need to provide the screening target and project requirements, and the scientists of Tek Biotech can provide a reasonable and customized solution to meet the customer's needs and solve the customer's scientific research problems. Tek Biotech's scientists will provide reasonable and customized solutions to solve customers' scientific research problems.

█ Nucleic Acid Aptamer Screening Service

Based on the advantages of small molecular weight, low immunogenicity, high tissue permeability, rapid mass synthesis in vitro, easy modification, and high stability, more and more researchers prefer nucleic acid aptamers, which have smaller molecular weights than nanoantibodies and peptides, as the research objects of targeted drug development. Nucleic acid aptamers have a specific three-dimensional spatial conformation and function through specific binding with the target, which has a broad prospect in biomedical research (including but not limited to clinical diagnosis, gene therapy, target-specific molecule drug development, biosensors, etc.) and environmental detection, and it is also the hotspot of the current targeted small molecule drug discovery and development research.

Tek Biotech can provide a variety of antigen screening (including but not limited to protein, peptide, amino acid, small molecule, etc.), and aptamer screening methods (e.g., magnetic bead-SELEX, cellular-SELEX, capture-SELEX, etc.), and the commonly used screening method is magnetic bead screening. For special samples, the screening method will be different, for example, drug small molecules need to be screened for aptamers, and small molecule modification technology is often used. Tek Biotech's scientists will evaluate the needs of the customer's project and design the best solution for antigen modification and aptamer screening.

The nucleic acid aptamer screening process is shown in Figure 1:

Figure 1 Nucleic acid aptamer screening process (typical procedure for SELEX method)

█ Content and Periodicity of Services

█ Service Advantage

-- Multiple screening targets available: proteins, peptides, amino acids, small molecules, etc.

-- Library capacity of 10^10-10^11, sufficient to screen high-affinity nucleic acid aptamers for customer's targets.

-- Mature SELEX technology platform: the affinity of the aptamers obtained by screening can reach nM-pM level.

-- Supporting downstream validation experiments: affinity validation (including BLI and SPR affinity validation), competitive ELISA validation, flow-through blocking validation, etc.

-- Traceability of experimental records: Chinese and English lab reports, original lab records.

-- One-to-one customized solutions to meet the needs of various customers' research projects.

-- Wide range of applications: can be used for protein, nucleic acid, peptide, nanomaterials and other molecular interactions.

-- 6-10 rounds of pressure screening to obtain high affinity and high specificity nucleic acid aptamers.

-- Multiple screening methods: magnetic bead-SELEX, cell-SELEX, capture-SELEX, etc.